21
Hu Chuanmin, Huang Hongtao, Wang Jian, Yi Weijing, Li Peng, Gao Lihong: Macrophagocyte transfer inhibition factor monoclonal antibody and method for making same. Hu Chuanmin, September 26, 2007: CN200610070899

The invention discloses a preparing method of monoclonal antibody (hMIF) to against human macrophage transferring inhibitor and getting method of amino acid sequence in biological medicine engineering technical domain, which comprises the following steps: augmenting out of hMIF gene from human breas ...


22
Zhang Wei, Yao Wenjuan, Xu Xiaole, Wang Yuqin, Chen Xiangfan: Compound rhizoma polygonati oral liquid and preparation method thereof. Nantong University, ge lei, December 21, 2011: CN201110201940

The invention discloses compound rhizoma polygonati oral liquid and a preparation method thereof. The compound rhizoma polygonati oral liquid is prepared from rhizoma polygonati, Astragalus mongholicus, Semen Cuscutae, herba epimedii, Radix Ophiopogonis, Morinda officinalis, stilbene and sodium benz ...


23
Xiong Jie, Xu Pingxiang: Application of lycopene in preparation of medicament for treating cerebral ischemia injury. Capital Medical University, guan chang ren fenghua, January 4, 2012: CN201110299863

The invention discloses application of lycopene in preparation of a medicament for treating cerebral ischemia injury. In the application, the medicament for treating cerebral ischemia injury is at least one of the following components as shown in 1) to 3): 1) a medicament for treating encephaledema; ...


24
PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY CONTAINING FACTOR VII FUSION PROTEIN. January 5, 2017: US20170000861-A1

The present invention provides a pharmaceutical composition with improved stability, comprising a fusion protein comprising factor VII(FVII) and transferrin, as an active ingredient, wherein the transferrin is linked to the C-terminus of the FVII; and trehalose or glycine as a bulking agent. The com ...


25
METHODS AND COMPOSITIONS FOR TREATING FATIGUE ASSOCIATED WITH DISORDERED SLEEP USING VERY LOW DOSE CYCLOBENZAPRINE. March 9, 2017: US20170065538-A1

The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine The present invention further relates to a bi ...


26
FUMARATE ESTER DOSAGE FORMS. March 2, 2017: US20170056360-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


27
FUMARATE ESTER DOSAGE FORMS. March 2, 2017: US20170056359-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


28
FUMARATE ESTER PHARMACEUTICAL COMPOSITIONS. March 16, 2017: US20170071891-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.


29
METHOD OF REMOVING AN INFLATED IMPLANT FROM A BLADDER. March 9, 2017: US20170065160-A1

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. In one embodiment, removal is accomplished by reducing the inflated implant from an enla ...


30
METHOD OF REMOVING AN INFLATED IMPLANT FROM A BLADDER. March 23, 2017: US20170079761-A1

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. In one embodiment, removal is accomplished by reducing the inflated implant from an enla ...



Click the thumbnails below to visualize the patent trend.